Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
View Patent ↗The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
1. A formulation comprising a biologically acceptable carrier and a compound of the following formula,
or a pharmaceutically acceptable salt thereof.
2. The formulation of claim 1 , wherein, upon administration, active hydrocodone is released from the compound of the formula Bz-HC through first-pass metabolism.
3. The formulation of claim 1 , in a dosage form selected from the group consisting of: a tablet, a capsule, a caplet, a suppository, a troche, a lozenge, an oral powder, a solution, an oral film, a thin strip, a slurry, and a suspension.
4. The formulation of claim 1 further comprising at least one excipient.
5. The formulation of claim 4 , wherein the excipient is an antiadherent, binder, coating, disintegrant, filler, flavor, color, glidant, lubricant, preservative, sorbent, sweetener or combinations and mixtures thereof.
6. The formulation of claim 1 , wherein the compound of the formula Bz-HC is a pharmaceutically acceptable salt.
7. The formulation of claim 1 including from about 0.5 mg to about 100 mg or higher of the compound of the formula Bz-HC.
8. The formulation of claim 1 , wherein the compound of the formula (Bz-HC) or pharmaceutically acceptable salt thereof is provided in an amount sufficient to provide a therapeutically bioequivalent AUC when compared to unconjugated hydrocodone.
9. The formulation of claim 1 , wherein in the compound of the formula (Bz-HC) or pharmaceutically acceptable salt thereof is provided in an amount sufficient to provide a therapeutically bioequivalent AUC and Cmax when compared to an equivalent molar amount of unconjugated hydrocodone.
10. The formulation of claim 1 , wherein in the compound of the formula (Bz-HC) or pharmaceutically acceptable salt thereof is provided in an amount sufficient to provide a therapeutically bioequivalent AUC and a lower Cmax when compared to an equivalent molar amount of unconjugated hydrocodone.
11. The formulation of claim 6 , wherein the pharmaceutically acceptable salt of the compound of the formula (Bz-HC) is an acetate, L-aspartate, besylate, bicarbonate, carbonate, D-camsylate, L-camsylate, citrate, edisylate, fumarate, gluconate, hydrobromide/bromide, hydrochloride/chloride, D-lactate, L-lactate, D,L-lactate, D,L-malate, L-malate, mesylate, pamoate, phosphate, succinate, sulfate, D-tartrate, L-tartrate, D,L-tartrate, meso-tartrate, benzoate, gluceptate, D-glucuronate, hybenzate, isethionate, malonate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, stearate, tosylate, acefyllinate, aceturate, aminosalicylate, ascorbate, borate, butyrate, camphorate, camphocarbonate, decanoate, hexanoate, cholate, cypionate, dichloroacetate, edentate, ethyl sulfate, furate, fusidate, galactarate (mucate), galacturonate, gallate, gentisate, glutamate, glutarate, glycerophosphate, heptanoate (enanthate), hydroxybenzoate, hippurate, phenylpropionate, iodide, xinafoate, lactobionate, laurate, maleate, mandelate, methanesulfonate, myristate, napadisilate, oleate, oxalate, palmitate, picrate, pivalate, propionate, pyrophosphate, salicylate, salicylsulfate, sulfosalicylate, tannate, terephthalate, thiosalicylate, tribrophenate, valerate, valproate, adipate, 4-acetamidobenzoate, camsylate, octanoate, estolate, esylate, glycolate, thiocyanate, undecylenate or mixtures and combinations thereof.
12. The formulation of claim 11 , wherein the pharmaceutically acceptable salt is a hydrochloride salt.
13. The formulation of claim 1 , wherein the ratio of the compound of the formula (Bz-HC) to the pharmaceutically acceptable salt thereof ranges from about 1:0.1 to about 1:10.
14. The formulation of claim 1 , wherein the ratio of the compound of the formula (Bz-HC) to the pharmaceutically acceptable salt thereof ranges from about 1:0.5 to about 1:2.
15. The formulation of claim 1 , wherein the ratio of the compound of the formula (Bz-HC) to the pharmaceutically acceptable salt thereof is about 1:1.
16. A pharmaceutical kit comprising from about 1 to about 100 individual dosages of the formulation of claim 1 .